ClinicalTrials.gg
Active, not recruitingNCT02362503Updated Aug 21, 2026Results posted

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

A Phase 3 interventional study of BMS-663068 and Placebo in HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 139 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
35th of 210
371 · median 82
Started
2015
with 9 others
Phase 3
65 of 266
1 open now
Primary completion
2016-08
later than 0 of 26 live
Registered
161st of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 35th largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2015, is one of 65 in phase 3, reaches primary completion later than 0 of the 26 other live ones, and was the 161st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and non-pregnant women with chronic -1 infection
  • Antiretroviral-experienced with documented historical or baseline resistance, intolerability, and/or to antiretrovirals in at least three classes
  • Failing current antiretroviral regimen with a confirmed plasma HIV-1 RNA ≥ 400 c/mL (first value from Investigator, second from Screening labs)
  • Must have ≤ 2 classes with at least 1 but no more than 2 fully-active antiretrovirals remaining which can be effectively combined to form a viable new regimen, based on current and/or documented historical resistance testing and tolerability and safety
  • Able to receive ≥ 1 fully active approved antiretroviral as part of the OBT from Day 9 onwards in the Randomized Cohort
  • Subjects without any remaining fully active approved antiretroviral may be enrolled in the Non-Randomized Cohort

Exclusion criteria

Exclusion Criteria:

  • Chronic untreated virus (HBV) (however, patients with chronic treated HBV are eligible)
  • -2 infection
  • (ALT) or aspartate aminotransferase (AST) > 7 x
  • Alkaline Phosphatase > 5 x ULN
  • ≥ 1.5 x Upper limit of normal (ULN) (unless subject is currently on atazanavir and has predominantly unconjugated hyperbilirubinemia)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    A1: BMS-663068

    Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.

    Drug: BMS-663068

  • Active comparator
    B1: Placebo + BMS-663068

    Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.

    Drug: BMS-663068 · Other: Placebo

  • Experimental
    BMS-663068

    BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.

    Drug: BMS-663068

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort

    Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.

    Time frame: Day 1 and Day 8

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort

    The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.

    Time frame: Day 1 and Day 8

  2. Percentage of Participants With HIV-1 RNA <40 c/mL at Weeks 24, 48 and 96-Randomized Cohort

    The durability of response (that is, the number of participants achieving HIV-1 RNA \<40 c/mL) at Weeks 24, 48 and 96 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24, 48 and 96 or those who changed OBT due to lack of efficacy through Weeks 24, 48 and 96 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA \<40 c/mL) at Weeks 24, 48 and 96 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

    Time frame: At Weeks 24, 48 and 96

  3. Number of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort

    An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

    Time frame: Up to Week 96 analysis cut-off date

  4. Number of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort

    Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

    Time frame: Baseline and up to Week 96 analysis cut-off date

  5. Number of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort

    Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

    Time frame: Baseline and up to Week 96 analysis cut-off date

  6. Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort

    Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

    Time frame: Up to Week 96 analysis cut-off date

  7. Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort

    CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.

    Time frame: Day 1 and Day 8

  8. Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort

    CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.

    Time frame: Day 1 and Day 8

  9. Change From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 96-Randomized Cohort

    Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

    Time frame: Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96

  10. Change From Baseline in CD4+ T- Cell Count Through Week 96-Randomized Cohort

    CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.

    Time frame: Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96

  11. Change From Baseline in CD4+ T- Cell Count Percentage Through Week 96

    Percentage CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.

    Time frame: Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96

  12. Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort

    Plasma samples were collected for emergent drug resistance testing. The number of participants with emergent viral genotypic substitutions of interest in the GP160 domain was identified by the next-generation sequencing (NGS) assay. Protocol defined virologic failure (PDVF) through Week 96 Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. The criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA \>=400 c/mL at any time after prior confirmed suppression to \<400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, \> 1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is \>=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA \>=400 c/mL at or after Week 24.

    Time frame: Week 96

  13. Number of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort

    The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, i.e., the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR\<1 indicates that FC is smaller on-treatment than at Baseline. FCR \>3 indicates that on-treatment FC is 3 times greater than it was at Baseline.

    Time frame: Week 96

07

Results

Posted Sep 18, 2018

Participant flow

This was a 2 cohort Phase 3 study conducted in heavily treatment experienced (HTE) participants infected with multi-drug resistant human immunodeficiency virus (HIV)-1. Participants were assigned to either the Randomized Cohort (participants received either fostemsavir or placebo) or Non-randomized Cohort (all participants received fostemsavir).

Double-blind Period-Up to 8 Days
Participant flow — Double-blind Period-Up to 8 Days
MilestoneRandomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BIDNon-randomized Cohort-fostemsavir 600 mg BID-Open Label Period
Started692030
Completed681990
Not completed140
Withdrew: Adverse event020
Withdrew: Death100
Withdrew: Lost to follow-up010
Withdrew: No longer meets study criteria010
Open Label Period-Up to 96 Weeks
Participant flow — Open Label Period-Up to 96 Weeks
MilestoneRandomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BIDNon-randomized Cohort-fostemsavir 600 mg BID-Open Label Period
Started6819999
Completed000
Not completed6819999
Withdrew: Other011
Withdrew: No longer meets criteria044
Withdrew: Pregnancy010
Withdrew: Non-compliance with study drug386
Withdrew: Lost to follow-up431
Withdrew: Death1715
Withdrew: Withdrawal by subject051
Withdrew: Adverse event324
Withdrew: Lack of efficacy396
Withdrew: Ongoing at the time of analysis5415961

Outcome measures

PrimaryMean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort

Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.

Time frame:
Day 1 and Day 8
Reported as:
Least squares mean · Log10 copies per milliliter (c/mL)
Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort
Log10 copies per milliliter (c/mL)Randomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BID
Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort-0.166 (-0.326 to -0.007)-0.791 (-0.885 to -0.698)
Statistical analysis
  • Randomized Cohort-Placebo vs Randomized Cohort-fostemsavir 600 mg BID · ANCOVA · p = <0.0001 (Hypothesis test:µfostemsavir=µPlacebo where µ is a common intercept.) · Mean difference (net): -0.625 · 95% CI -0.810 to -0.441Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.
SecondaryPercentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort

The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.

Time frame:
Day 1 and Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort
Percentage of participantsRandomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BID
>0.5 log10 c/mL18.84 (11.35 to 29.61)64.53 (57.74 to 70.79)
>1.0 log10 c/mL10.14 (5.00 to 19.49)45.81 (39.10 to 52.68)
Statistical analysis
  • Randomized Cohort-Placebo vs Randomized Cohort-fostemsavir 600 mg BID · Mean difference (net): 45.69 · 95% CI 32.95 to 55.45Difference between treatment groups (fostemsavir 600 mg BID-Placebo) and 95% confidence interval using Newcombe method is presented for \>0.5 log10 c/mL.
  • Randomized Cohort-Placebo vs Randomized Cohort-fostemsavir 600 mg BID · Mean difference (net): 35.67 · 95% CI 24.16 to 44.25Difference between treatment groups (fostemsavir 600 mg BID-Placebo) and 95% confidence interval using Newcombe method is presented for \>1.0 log10 c/mL.
SecondaryPercentage of Participants With HIV-1 RNA <40 c/mL at Weeks 24, 48 and 96-Randomized Cohort

The durability of response (that is, the number of participants achieving HIV-1 RNA \<40 c/mL) at Weeks 24, 48 and 96 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24, 48 and 96 or those who changed OBT due to lack of efficacy through Weeks 24, 48 and 96 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA \<40 c/mL) at Weeks 24, 48 and 96 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

Time frame:
At Weeks 24, 48 and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <40 c/mL at Weeks 24, 48 and 96-Randomized Cohort
Percentage of participantsRandomized Cohort
Week 2453 (47.0 to 58.8)
Week 4854 (47.7 to 59.5)
Week 9660 (54.0 to 65.6)
SecondaryNumber of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort

An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

Time frame:
Up to Week 96 analysis cut-off date
Reported as:
Count of participants · Participants
Number of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort
ParticipantsRandomized Cohort
SAE92
AELD14
SecondaryNumber of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort

Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

Time frame:
Baseline and up to Week 96 analysis cut-off date
Reported as:
Count of participants · Participants
Number of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort
ParticipantsRandomized Cohort
Albumin; n=2681
Alkaline phosphatase; n=2683
Alanine aminotransferase; n=26814
Amylase; n=2682
Aspartate aminotransferase; n=26810
Bicarbonate; n=2681
Direct bilirubin; n=26820
Bilirubin; n=2687
Calcium; n=2689
Cholesterol; n=22110
Creatine kinase; n=2686
Creatinine; n=26852
Estimated creatinine clearance; n=26875
Glucose/hyperglycemia; n=2676
Glucose/hypoglycemia; n=2672
Potassium/hyperkalemia; n=2684
Potassium/hypokalemia; n=2680
Low density lipoprotein (LDL) cholesterol; n=2168
Lipase; n=26813
Sodium/hypernatremia; n=2680
Sodium/hyponatremia; n=2680
Triglycerides; n=22111
Urate; n=2689
SecondaryNumber of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort

Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

Time frame:
Baseline and up to Week 96 analysis cut-off date
Reported as:
Count of participants · Participants
Number of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort
ParticipantsRandomized Cohort
Hemoglobin; n=26816
Neutrophils; n=26810
Platelets; n=2672
Leukocytes; n=2684
SecondaryNumber of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort

Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

Time frame:
Up to Week 96 analysis cut-off date
Reported as:
Count of participants · Participants
Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort
ParticipantsRandomized Cohort
Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort23
SecondaryChange From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort

CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.

Time frame:
Day 1 and Day 8
Reported as:
Least squares mean · Cells per cubic millimeter
Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort
Cells per cubic millimeterRandomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BID
Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort18.9 (4.7 to 33.0)18.5 (10.1 to 26.8)
Statistical analysis
  • Randomized Cohort-Placebo vs Randomized Cohort-fostemsavir 600 mg BID · Mean difference (net): -0.4 · 95% CI -16.8 to 16.0Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.
SecondaryChange in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort

CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.

Time frame:
Day 1 and Day 8
Reported as:
Least squares mean · Percentage of CD4+T- cells
Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort
Percentage of CD4+T- cellsRandomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BID
Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort0.243 (-0.216 to 0.703)0.860 (0.588 to 1.133)
Statistical analysis
  • Randomized Cohort-Placebo vs Randomized Cohort-fostemsavir 600 mg BID · Mean difference (net): 0.617 · 95% CI 0.082 to 1.151Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.
SecondaryChange From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 96-Randomized Cohort

Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

Time frame:
Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · Log10 c/mL
Change From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 96-Randomized Cohort
Log10 c/mLRandomized Cohort
Day 8; n=262-0.656 ± 0.7536
Week 4; n=262-2.051 ± 1.0717
Week 8; n=256-2.207 ± 1.1416
Week 12; n=248-2.237 ± 1.2105
Week 16; n=249-2.277 ± 1.2834
Week 24; n=246-2.297 ± 1.2788
Week 36; n=238-2.332 ± 1.2265
Week 48; n=233-2.324 ± 1.2876
Week 60; n=223-2.419 ± 1.1973
Week 72; n=221-2.427 ± 1.1542
Week 84; n=215-2.455 ± 1.1930
Week 96; n=214-2.476 ± 1.1984
SecondaryChange From Baseline in CD4+ T- Cell Count Through Week 96-Randomized Cohort

CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.

Time frame:
Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline in CD4+ T- Cell Count Through Week 96-Randomized Cohort
Cells per cubic millimeterRandomized Cohort
Day 8; n=25519.8 ± 60.98
Week 4; n=25948.9 ± 131.75
Week 8; n=25461.5 ± 113.47
Week 12; n=24979.0 ± 123.31
Week 16; n=24584.1 ± 107.26
Week 24; n=24790.4 ± 112.10
Week 36; n=234109.7 ± 119.50
Week 48; n=228138.9 ± 135.06
Week 60; n=215162.9 ± 157.69
Week 72; n=217172.1 ± 184.81
Week 84; n=203190.8 ± 165.63
Week 96; n=213204.7 ± 191.28
SecondaryChange From Baseline in CD4+ T- Cell Count Percentage Through Week 96

Percentage CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.

Time frame:
Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · Percentage of CD4+ T- cells
Change From Baseline in CD4+ T- Cell Count Percentage Through Week 96
Percentage of CD4+ T- cellsRandomized Cohort
Day 8; n=2550.75 ± 1.970
Week 4; n=2592.30 ± 4.643
Week 8; n=2542.36 ± 4.392
Week 12; n=2493.00 ± 4.945
Week 16; n=2453.51 ± 4.979
Week 24; n=2474.26 ± 4.828
Week 36; n=2345.06 ± 5.256
Week 48; n=2286.51 ± 5.531
Week 60; n=2157.00 ± 5.940
Week 72; n=2177.02 ± 5.726
Week 84; n=2037.68 ± 5.798
Week 96; n=2138.44 ± 6.409
SecondaryNumber of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort

Plasma samples were collected for emergent drug resistance testing. The number of participants with emergent viral genotypic substitutions of interest in the GP160 domain was identified by the next-generation sequencing (NGS) assay. Protocol defined virologic failure (PDVF) through Week 96 Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. The criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA \>=400 c/mL at any time after prior confirmed suppression to \<400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, \> 1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is \>=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA \>=400 c/mL at or after Week 24.

Time frame:
Week 96
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort
ParticipantsRandomized Cohort
Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort24
SecondaryNumber of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort

The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, i.e., the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR\<1 indicates that FC is smaller on-treatment than at Baseline. FCR \>3 indicates that on-treatment FC is 3 times greater than it was at Baseline.

Time frame:
Week 96
Reported as:
Count of participants · Participants
Number of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort
ParticipantsRandomized Cohort
<=119
>1 to 310
>3 to 105
>10 to 1001
>100 to 300010
>30008

Adverse events

Collected over On-treatment non-SAEs and SAEs were collected from the start of study treatment until Week 96 data cut-off date. The data presented for Randomized Cohort-Placebo and Randomized Cohort-fostemsavir 600 mg BID represent safety events during the double-blind period (Up to Day 8). The safety data presented in the Randomized Cohort-Total, Non-Randomized Cohort-fostemsavir 600 mg BID and Fostemsavir Total columns represent safety events during fostemsavir dosing until the Week 96 data cut-off date.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Cohort-Placebo2/69 (2.9%)2/69 (2.9%)16/69 (23.2%)
Randomized Cohort-fostemsavir 600 mg BID10/203 (4.9%)4/203 (2%)45/203 (22.2%)
Non-randomized Cohort-fostemsavir 600 mg BID17/99 (17.2%)48/99 (48.5%)92/99 (92.9%)
Randomized Cohort-Total12/271 (4.4%)92/271 (33.9%)214/271 (79%)
Total Fostemsavir29/370 (7.8%)140/370 (37.8%)306/370 (82.7%)
Most frequent serious events
Showing 10 of 196
Most frequent serious events
EventRandomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BIDNon-randomized Cohort-fostemsavir 600 mg BIDRandomized Cohort-TotalTotal Fostemsavir
PneumoniaInfections and infestations0/692/2033/9912/27115/370
Acute kidney injuryRenal and urinary disorders0/690/2034/992/2716/370
CellulitisInfections and infestations0/690/2033/995/2718/370
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/690/2033/991/2714/370
Pneumocystis jirovecii pneumoniaInfections and infestations0/690/2033/991/2714/370
SepsisInfections and infestations0/690/2033/991/2714/370
Deep vein thrombosisVascular disorders0/690/2032/991/2713/370
PyrexiaGeneral disorders0/690/2032/991/2713/370
SeizureNervous system disorders0/690/2032/991/2713/370
AstheniaGeneral disorders0/690/2032/990/2712/370
Most frequent other events
Showing 10 of 39
Most frequent other events
EventRandomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BIDNon-randomized Cohort-fostemsavir 600 mg BIDRandomized Cohort-TotalTotal Fostemsavir
DiarrhoeaGastrointestinal disorders3/698/20325/9960/27185/370
NauseaGastrointestinal disorders4/6914/20321/9945/27166/370
NasopharyngitisInfections and infestations0/692/20319/9934/27153/370
PyrexiaGeneral disorders1/691/20316/9930/27146/370
FatigueGeneral disorders2/693/20316/9918/27134/370
Upper respiratory tract infectionInfections and infestations0/691/20315/9942/27157/370
HeadacheNervous system disorders5/696/20312/9936/27148/370
InfluenzaInfections and infestations0/691/20313/9926/27139/370
BronchitisInfections and infestations0/690/2035/9934/27139/370
CoughRespiratory, thoracic and mediastinal disorders1/690/20311/9933/27144/370

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Randomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BIDNon-randomized Cohort-fostemsavir 600 mg BID-Open Label PeriodTotal
Mean43.0 ± 11.0245.2 ± 12.7248.1 ± 11.5345.6 ± 12.20
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BIDNon-randomized Cohort-fostemsavir 600 mg BID-Open Label PeriodTotal
Female12601082
Male5714389289
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Randomized Cohort-PlaceboRandomized Cohort-fostemsavir 600 mg BIDNon-randomized Cohort-fostemsavir 600 mg BID-Open Label PeriodTotal
Race customized — Black or African American18422383
Race customized — American Indian or Alaska Native1618
Race customized — Asian0202
Race customized — Native Hawaiian or other Pacific islander0101
Race customized — White4813774259
Race customized — Mixed1618
Race customized — Hispanic0202
Race customized — Mestizo1203
Race customized — North African0101
Race customized — Mulatto0101
Race customized — Brown0202
Race customized — White and African descent0101
08

Study locations

139 sites
  • GSK Investigational Site
    Los Angeles, California 90008, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Palm Springs, California 92262, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Denver, Colorado 80262, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20007, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20009, United States
  • GSK Investigational Site
    Ft. Pierce, Florida 34982, United States
  • GSK Investigational Site
    Orlando, Florida 32801, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Wilton Manors, Florida 33306, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Atlanta, Georgia 30312, United States
  • GSK Investigational Site
    Savannah, Georgia 31401, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Chicago, Illinois 60613, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Baltimore, Maryland 21287, United States
  • GSK Investigational Site
    Boston, Massachusetts 211, United States
  • GSK Investigational Site
    Southfield, Michigan 48075, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Newark, New Jersey 07102, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New York, New York 10010, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    The Bronx, New York 10467, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267-0405, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74135, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    Dallas, Texas 75235, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Buenos Aires, C1141ACG, Argentina
  • GSK Investigational Site
    Buenos Aires, C1202ABB, Argentina
  • GSK Investigational Site
    Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1405CKC, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1155ADP, Argentina
  • GSK Investigational Site
    Córdoba, 5000, Argentina
  • GSK Investigational Site
    Córdoba, X5000JJS, Argentina
  • GSK Investigational Site
    Rosario, S2000PBJ, Argentina
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
  • GSK Investigational Site
    Antwerp, 2000, Belgium
  • GSK Investigational Site
    Brussels, 1000, Belgium
  • GSK Investigational Site
    Belo Horizonte, 30130-100, Brazil
  • GSK Investigational Site
    Campinas, 13015-080, Brazil
  • GSK Investigational Site
    Curitiba, 80240-280, Brazil
  • GSK Investigational Site
    Porto Alegre, 90035-903, Brazil
  • GSK Investigational Site
    RibeirAo PretoSP, 14048-900, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 21040-900, Brazil
  • GSK Investigational Site
    Salvador, 40110-060, Brazil
  • GSK Investigational Site
    São Paulo, 01416-901, Brazil
  • GSK Investigational Site
    São Paulo, 04040-002, Brazil
  • GSK Investigational Site
    São Paulo, 04121-000, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V6H3N1, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 1Y8, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 5B1, Canada
  • GSK Investigational Site
    Sainte-Foy, Quebec G1V 4G5, Canada
  • GSK Investigational Site
    Santiago, 7500520, Chile
  • GSK Investigational Site
    Santiago, 8330074, Chile
  • GSK Investigational Site
    Santiago, 8360159, Chile
  • GSK Investigational Site
    Santiago, 8900088, Chile
  • GSK Investigational Site
    Temuco, 4781151, Chile
  • GSK Investigational Site
    Bogotá, 110111, Colombia
  • GSK Investigational Site
    Bogotá, 111311, Colombia
  • GSK Investigational Site
    Cali, 760032, Colombia
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Marseille, 13009, France
  • GSK Investigational Site
    Nantes, 44093, France
  • GSK Investigational Site
    Paris, 75004, France
  • GSK Investigational Site
    Paris, 75013, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Paris, 75475, France
  • GSK Investigational Site
    Paris, 75571, France
  • GSK Investigational Site
    Paris, 75970, France
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Berlin, 12157, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Dortmund, 44137, Germany
  • GSK Investigational Site
    Frankfurt, 60590, Germany
  • GSK Investigational Site
    Freiburg im Breisgau, 79106, Germany
  • GSK Investigational Site
    München, 80336, Germany
  • GSK Investigational Site
    Athens, 16121, Greece
  • GSK Investigational Site
    Thessaloniki, 54636, Greece
  • GSK Investigational Site
    Dublin, Dublin 7, Ireland
  • GSK Investigational Site
    Milan, 20127, Italy
  • GSK Investigational Site
    Milan, 20157, Italy
  • GSK Investigational Site
    Modena, 41124, Italy
  • GSK Investigational Site
    Monza MB, 20900, Italy
  • GSK Investigational Site
    Roma, 00149, Italy

Showing the first 100 of 139 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHTE Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493. PubMed 32212519 ↗
  • Benlarbi M, Richard J, Clemente T, Bourassa C, Tolbert WD, Prakash M, Chandravanshi M, Clark A, Pazgier M, Durand M, Castagna A, Finzi A. Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV. J Infect Dis. 2026 Feb 18;233(2):247-256. doi: 10.1093/infdis/jiaf461. PubMed 40990223 ↗
  • Clark A, Prakash M, Chabria S, Pierce A, Castillo-Mancilla JR, Wang M, Du F, Tenorio AR. Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study. Open Forum Infect Dis. 2024 Aug 26;11(9):ofae469. doi: 10.1093/ofid/ofae469. eCollection 2024 Sep. PubMed 39233711 ↗
  • Llibre JM, Aberg JA, Walmsley S, Velez J, Zala C, Crabtree Ramirez B, Shepherd B, Shah R, Clark A, Tenorio AR, Pierce A, Du F, Li B, Wang M, Chabria S, Warwick-Sanders M. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study. Front Immunol. 2024 May 28;15:1394644. doi: 10.3389/fimmu.2024.1394644. eCollection 2024. PubMed 38863717 ↗
  • Aberg JA, Shepherd B, Wang M, Madruga JV, Mendo Urbina F, Katlama C, Schrader S, Eron JJ, Kumar PN, Sprinz E, Gartland M, Chabria S, Clark A, Pierce A, Lataillade M, Tenorio AR. Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1. Infect Dis Ther. 2023 Sep;12(9):2321-2335. doi: 10.1007/s40121-023-00870-6. Epub 2023 Sep 26. PubMed 37751019 ↗
  • Gartland M, Cahn P, DeJesus E, Diaz RS, Grossberg R, Kozal M, Kumar P, Molina JM, Mendo Urbina F, Wang M, Du F, Chabria S, Clark A, Garside L, Krystal M, Mannino F, Pierce A, Ackerman P, Lataillade M. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0175121. doi: 10.1128/aac.01751-21. Epub 2022 May 3. PubMed 35502922 ↗
  • Anderson SJ, Murray M, Cella D, Grossberg R, Hagins D, Towner W, Wang M, Clark A, Pierce A, Llamoso C, Ackerman P, Lataillade M. Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals. Patient. 2022 Jan;15(1):131-143. doi: 10.1007/s40271-021-00534-y. Epub 2021 Jun 28. PubMed 34180035 ↗
  • Lataillade M, Lalezari JP, Kozal M, Aberg JA, Pialoux G, Cahn P, Thompson M, Molina JM, Moreno S, Grinsztejn B, Diaz RS, Castagna A, Kumar PN, Latiff GH, De Jesus E, Wang M, Chabria S, Gartland M, Pierce A, Ackerman P, Llamoso C. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020 Nov;7(11):e740-e751. doi: 10.1016/S2352-3018(20)30240-X. PubMed 33128903 ↗
  • Lagishetty C, Moore K, Ackerman P, Llamoso C, Magee M. Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis. Clin Transl Sci. 2020 Jul;13(4):769-776. doi: 10.1111/cts.12763. Epub 2020 Mar 19. PubMed 32027457 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Aug 2016, 17 months.

Results were first posted in Sep 2018, 2 years 1 month after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 17 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2015
First posted
Feb 13, 2015
StartActual
Feb 23, 2015
Primary completionActual
Aug 18, 2016
CompletionEst.
Oct 22, 2026
Results first posted
Sep 18, 2018
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02362503
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Feb 13, 2015
Start date
Feb 23, 2015
Primary completion
Aug 18, 2016
Completion
Oct 22, 2026 (estimated)
Results posted
Sep 18, 2018
Last update
Aug 21, 2026

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fostemsavir

Start the discussion